About PGDx

About PGDx

Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.

We help pharmaceutical/biotechnology companies and researchers develop the personalized medicines of the future and our CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians.

Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer.


Our founders, Luis Diaz, MD, and Victor Velculescu, MD, PhD, are internationally recognized leaders in cancer genomics who have extensive experience in the practical application of advanced genomic technologies to drug development and clinical practice. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.

Next-generation sequencing solution

sequencing solution

Our Philosophy

PGDx brings proprietary technology to each cancer genome analysis project and our CLIA-validated facility assures the highest specificity and sensitivity for your samples.

  • We approach every project and partnership through a comprehensive analysis of cancer genomes to seek out bona fide somatic mutations in cancer.

  • We strive to decipher the complexity of cancer by continually investing in our proprietary bioinformatics, filtering capabilities, and inspection approaches with a goal to accurately reveal sequence and structural alterations and important driver mutations found across multiple cancer types.

  • We instill a culture of teamwork and collaboration to empower our organization with speed, accuracy, adaptability, and innovation.